



Oncolytic Virus Therapy Alters the Secretome of Targeted Glioblastoma Cells

Jakub Godlewski, Mohamed Farhath, Franz L. Ricklefs, Carmela Passaro, Klaudia Kiel, Hiroshi Nakashima, E. Antonio Chiocca and Agnieszka Bronisz



Figure S1. *a*,*b*: Principal component (PC) (*a*), and matrix correlation analysis (*b*) based on all mRNA transcripts (ArraystarTM human mRNA array, n = 6). *c*,*d*: Heatmap with unsupervised hierarchical clustering for GSCs mock or OV infected are shown separately for OV slow-responding (*c*, n = 3 per variant – light blue) and OV fast-responding (*d*, n = 3 per variant – dark blue) GSCs based on mRNA transcripts (n = 31555 genes on Arraystar[™] human mRNA array). e,f: Scatter plots of genes from GSCs mock, or OV infected are shown separately for OV slow-responding (e, n = 3 per variant, affected genes – light blue) and OV fast-responding (f, n = 3 per variant, affected genes – dark blue) GSCs. Pearson correlation values are disclosed. g,h: Gene ontology analysis of biological processes prevalent among genes deregulated upon OV infection in OV slow-responding (g, down-regulated – top, up-regulated – bottom), and OV fast-responding (h, down-regulated – top, up-regulated – bottom) GSCs.



Figure S2. a: Flow chart of experimental procedures of secretome fractionation. BioRender (https://biorender.com/) software was used. **b:** Representative micrographs of OV/EV tandems by transmission electron microscopy. Red arrows - EV, white arrows – OV; scale bar: 500nm. **c:** Densitometric analysis of Coomassie Blue stained gels with EV-depleted proteins secreted by mock and OV infected GSCs. **d:** Representative micrographs of EVs secreted by mock or OV infected GSCs by transmission electron microscopy; scale bar: 500nm. **e:** Mass spectroscopy analysis of EV protein secreted by mock or OV infected GSCs by total peptide hits number. Data for human and viral proteins pooled (n = 3 per variant). **f:** Mass spectroscopy analysis of EV protein secreted by mock and OV infected GSCs by relative quantification of total protein content per cell (n = 3 per variant). **g:** Mass spectroscopy analysis of markers protein detected in EV and EV-depleted fraction respectively. Data represented by heatmap.



Figure S3. *a,b*: Gene ontology analysis of biological processes (BP) and cellular processes (CP) prevalent among proteins detected in EV-depleted (**a**), and EV (**b**) fractions of the secretome; the color bar for enrichment in each category GSCs. **c**: Bar analysis of protein localization from EV-depleted (top, n = 1203) and EV fractions (bottom, n = 2088) in Subcell Barcode dataset based on the mass-spectroscopy analysis of proteins in secretome (S), nucleus (N), cytoplasm (C), or mitochondrial (M) compartments. **d**: Representative micrographs of selected proteins in mock or OV infected GSCs by fluorescent confocal microscopy; with an antibody signal, scale bar: 25μ m. **e**: Bar analysis of cell-line-specific localization of TPM3, MST1, CD276, and CD320 in Subcell Barcode dataset based on the mass-spectroscopy analysis.



Figure S4. a: Heatmap with supervised hierarchical clustering for GSCs mock or OV infected (n = 6 per variant) based on mass spectroscopy analysis in EV-depleted and EV fractions (n = 1919 proteins, cutoffs between groups mock *vs*. OV in both fractions: p-value < 0.05, FD > 2). **b:** Heatmap with unsupervised clustering for GSCs mock or OV infected (n = 6 per variant) based on mRNA transcripts (n = 1919 genes encoding for proteins shown on a panel **a**, based on ArraystarTM human mRNA array). **c,d:** Principal component (PC) (**c**), and matrix correlation analysis (**d**) based on mRNA transcripts (n = 1919 genes encoding for proteins shown on a panel **a**, based on MRNA transcripts (n = 1919 genes encoding for proteins shown on a panel **a**, based on ArraystarTM human mRNA array, n = 6 per variant). **e**,**f:** The list of 1500 genes (see **Fig. 4a**) was filtered out to top-50 varied genes using TCGA data associated with glioblastoma. **e**) Heatmap of genes with color annotations according to prognostic index stratification cluster (horizontal cluster) and FD upon OV infection (vertical cluster). **f**) Kaplan-Meier curves show survival analysis stratified according to their prognostic index (see panel **e**); hazard ratio (HR). **g:** A hierarchical clustering tree summarizes the biological functions of top-50 survival-predictive genes. Bigger dots indicate more significant p-values. **h:** Heatmap classify GSCs mock, or OV infected (n = 6 per variant) using four algorithms to estimate microenvironmental traits based on gene expression (n = 1500) signatures. **i:** Heatmaps classify GSCs (n = 6 per variant) to deconvolute secretome profiles into mock or OV infected cells (**top**) and immune cell type (**bottom**) of specific profiles based on immune response protein signatures (n = 220); color bars indicate the type of immune cells and EV/EV-depleted proteins.

Table S1. Information about all reagents and resources used in the preparation of the manuscript.

REAGENT or RESOURCE	SOURCE	IDENTIFIER	
	Antibodies		
TPM3 Rabbit RRID AB_2633251	Thermo Fisher	720306	
MST1 Rabbit RRID AB_11157025	Thermo Fisher	PA5-22015	
CD276 Rabbit RRID AB_2789731	Thermo Fisher	PA5-82573	
CD320 Rabbit RRID AB_2664869	Thermo Fisher	PA5-67296	
CD63 Mouse (TS63)	Abcam	AB59479	
Secondary Goat anti-Rabbit polyclonal	Thermo Fisher	32460	
	Bacterial and Virus Strains		
BL21 Star (DE3) Chemically Compe- tent <i>E. coli</i>	Thermo Fisher	C601003	
Oncolytic herpes simplex virus type 1 (oHSV) rQNestin34.5	48	NA	
	Biological Samples		
Patient-derived GSCs	49	N/A	
Chemicals, Peptides, and Recombinant Proteins			
EGF	Pepro Tech	AF-100-15	
FGF2	Pepro Tech	100-18C	
B27	Gibco	21103049	
Neurobasal	Gibco	21103049	
TRIzol [™] Reagent	ThermoFisher	15596018	
	Critical Commercial Assays		
Power Up SYBR Green Master Mix	Thermo Fisher	A25743	
TaqMan Fast Advanced Master Mix	Thermo Fisher	4444963	
Agilent whole human genome micro- array	Arraystar	Agilent-026652 4x44K v2	
iScript™ cDNA Synthesis Kit	Bio-Rad	1708890	
	Deposited Data		
Mass spectrometry	This paper	Supplemental spreadsheets Table 2	
Genome microarray	This paper	Deposition: GSE155247	
	qPCR primers:		

TPM3:		
F: 5'-GA-		
GAGGTATGAAGGTTATTCA-3'		
R: 5'-ATCACCACCTTAC-		
GAGCCACC-3'		
MST1:		
F: 5'-GACAGCCCTCACGTAGTCAA -		
3'		
R: 5'-AGGAGCCATCCAAAACGGG-3'		
CD276:		
F: 5′-		
GTGGGGCTGTCTGTCTGTCTCAT-3'	Invitrogen	N/A
R: 5'-CTGTCAGAG-		
TGTTTCAGAGGCT-3'		
CD320:		
F: 5'-CTGCGACAGGGACTTGGA-3'		
R: 5'-GGGTACATGGCTCAATCCTG-		
3'		
18S rRNA:		
F: 5'-GGCCCTGTAATT-		
GGAATGAGTC-3'		
R: 5'-CCAAGATCCAACTAC-		
GAGCTT-3'		
	Recombinant DNA	
pCSCMV PalmtdTomato	50	N/A
	Software and Algorithms	
dchip with R package	F1	https://sites.google.com/site/dchip-
version dChip 2010.01	51	<u>soft/home</u>
ShinyGO v0.61	52	http://bioinformatics.sdstate.edu/go/
		accessed on: 01.03.2019
	53	https://gbm-biodp.nci.nih.gov
GBM biodiscovery portal		accessed on: 01.03.2019
	54	http://gliovis.bioinfo.
GlioVis:		accessed on: 15.01.2020
TCGA GBM	28	https://www.cancer.gov/
		accessed on: 01.03.2020
Subcellbarcode	55	http://www.subcellbarcode.org
BioRender	NA	https://biorender.com/

Table S2. Mass spectroscopy analysis of two protein fractions EV-depleted and EV: please see the <u>link</u>.